The phase 1 trial results were presented in greater detail in two posters at ASCO 2017 in Chicago this week. Professor Phil Clingan presented a poster: Deflexifol (a novel formulation of 5FU) Phase 1 Dose Escalation Study of Infusional or Bolus Schedules After Failure of Standard Treatment Clingan P. et al J Clin Oncol 35, 2017 […]
David Ranson will be presenting the Deflexifol opportunity to potential investors in Singapore, Hong Kong and Shanghai as part of AusBiotech’s Asian Investment Series, March 21 – 28, 2017. See http://ausbiotechinvestment.com.au/ for more details.
A poster presentation by Professor Phil Clingan summarizing phase 1 results has been presented at the ASCO GI conference, San Francisco, January 19-21, 2017. J Clin Oncol 35, 2017 (suppl 4S; abstract TPS812)
Preclinical evaluation of novel, all-in-one formulations of 5-fluorouracil and folinic acid with reduced toxicity profiles. Click to read this article.
Deflexifol (formerly Fluorodex) maintains in-vitro potency, overcomes incompatibility of 5-fluorouracil and folinic acid and may reduce phlebitis, catheter blockages and thromboembolic events. Development and assessment of novel all-in-one parenteral formulations with integrated anticoagulant properties for the concomitant delivery of 5-fluorouracil and calcium folinate. Read our article signalling improved patient outcomes from Deflexifol.
New hope being offered by Deflexifol to chemotherapy patients. Read here about new hope for chemotherapy patients.
Deflexifol is a new way of using an older drug. Read more.